Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 20;12:839816. doi: 10.3389/fonc.2022.839816

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Reichrath, Biersack, Wagenpfeil, Schöpe, Pföhler, Saternus and Vogt

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Vitamin D status is associated with LDH s.c. in advanced melanoma patients treated with BRAF/MEK and/or immune checkpoint inhibitors. During the complete OP, LDH s.c. was significantly lower (-170.826 U/l; p = 0.019) in patients with average 25(OH)D s.c. ≥10 ng/ml as compared to severely vitamin D-deficient individuals [average 25(OH)D s.c <10 ng/ml]. In general, an increase in average 25(OH)D s.c. of 1 ng/ml was associated with a significant reduction of LDH s.c. of 3.84 U/l (p = 0.034). Rounding error may occur. Number of patients may differ from total sample sizes due to missing data.